What is BioSensics?
Founded in 2007 by a trio of Harvard scientists, BioSensics specializes in the development of sophisticated wearable sensors designed for clinical trials, remote patient monitoring, and comprehensive health assessment. With over 17 years of rigorous research, the company has successfully pioneered the integration of digital biomarkers into the study of neurological and rare disorders. By providing robust data collection tools, BioSensics enables pharmaceutical companies and healthcare providers to achieve higher precision in symptom measurement, effectively transforming how chronic conditions are monitored and managed in real-world settings.
How much funding has BioSensics raised?
BioSensics has raised a total of $2.9M across 2 funding rounds:
Grant
$2.5M
Debt
$350K
Grant (2017): $2.5M with participation from National Institutes of Health
Debt (2020): $350K led by PPP
Key Investors in BioSensics
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical grant funding for scientific innovation.
PPP
Public-Private Partnership
What's next for BioSensics?
With this latest capital injection, BioSensics is well-positioned to scale its digital health platform and expand its footprint in the global clinical research market. The strategic focus will likely shift toward the commercialization of its validated biomarkers and the enhancement of its wearable sensor ecosystem. As the demand for decentralized clinical trials and remote patient monitoring continues to accelerate, BioSensics is poised to leverage its deep scientific heritage to drive innovation in personalized medicine and long-term health outcomes, ensuring its continued relevance in an increasingly data-driven medical environment.
See full BioSensics company page
